Librela® (bedinvetmab injection) is the first and only monthly injective anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy for dogs with osteoarthritis (OA) pain. Newsweek shares an inspiring story about how Librela helped a senior dog gain a new lease on life.
IMPORTANT SAFETY INFORMATION: Librela is for use in dogs only. Women who are pregnant, trying to conceive or breastfeeding should take extreme care to avoid self-injection. Hypersensitivity reactions, including anaphylaxis, could potentially occur with self-injection. Librela should not be used in breeding, pregnant, or lactating dogs. Librela should not be administered to dogs with known hypersensitivity to bedinvetmab. Adverse events reported post-approval include ataxia (lack of balance/coordination), anorexia (loss of appetite), lethargy (tiredness), emesis (vomiting), and polydipsia (increased drinking). The most common adverse events reported in a clinical study were urinary tract infections, bacterial skin infections and dermatitis (skin irritation/inflammation). See full Prescribing Information.
See the Client Information Sheet for more information about Librela.
